P01-08Dynamin 2 inhibitors as novel therapeutic agents in cervical cancer cells

17. Cervical neoplasia
L. Yoo-Young 1, K. Byoung-Gie 1, B. Duk-Soo 1, L. Jeong-Won 1, C. Chel Hun 1, K. Tae-Joong 1.
1Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (Korea, Republic of)

Background / Objectives

We investigate the possibility of dynamin 2 as a potential treatment target in cervical cancer cells using various dynamin 2 inhibitors.


Methods

Tissue microarray for the expression of dynamin 2 was performed in 208 early cervical cancer patients and analyzed the association between expression of dynamin 2 and primary tumor characteristics such as tumor size and depth of invasion. Then we performed in vitro using dynamin 2 inhibitors including MiTMAB, OcTMAB, Dynasore, and DD-6 on HeLa cells with proliferation, apoptosis, and migration assay.


Results

When we compare the expression level of Dynamin 2 based on the pathological findings, tumor size more than 2 cm and tumor invasion more than half of the entire cervix were associated with higher proportion of any dynamin 2 expression compared with no expression (+1, +2, and +3 vs. 0,  P = 0.013, P = 0.045). All of dynamin 2 inhibitors including MiTMAB, OcTMAB, Dynasore, and DD-6 significantly decreased proliferation and increased apoptotic activity in HeLa cells. And also these all inhibitors significantly decreased MMP-9 expression compared with control in HeLa cells. In migration assay, dynasore and DD-6 decreased migration in in HeLa cells coated by laminin 1. However, DD-6 most strongly decreased migration performance in fibronectin-coated wells. 


Conclusion

Targeting dynamin 2 with various specific inhibitors may be a promising new approach for the treatment of cervical cancer in the future.


References

1.          Hirte H, Kennedy EB, Elit L, Fung Kee Fung M. Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline. Current oncology (Toronto, Ont). 2015 Jun;22(3):211-9. PubMed PMID: 26089720. Pubmed Central PMCID: PMC4462531. Epub 2015/06/20. eng.

2.          Lee YY, Song SY, Do IG, Kim TJ, Kim BG, Lee JW, et al. Dynamin 2 expression as a biomarker in grading of cervical intraepithelial neoplasia. European journal of obstetrics, gynecology, and reproductive biology. 2012 Oct;164(2):180-4. PubMed PMID: 22959143. Epub 2012/09/11. eng.

3.          Lee YY, Do IG, Park YA, Choi JJ, Song SY, Kim CJ, et al. Low dynamin 2 expression is associated with tumor invasion and metastasis in invasive squamous cell carcinoma of cervix. Cancer biology & therapy. 2010 Aug 15;10(4):329-35. PubMed PMID: 20574164. Epub 2010/06/25. eng.

4.          Lee YY, Kim TJ, Kim JY, Choi CH, Do IG, Song SY, et al. Genetic profiling to predict recurrence of early cervical cancer. Gynecologic oncology. 2013 Dec;131(3):650-4. PubMed PMID: 24145113. Epub 2013/10/23. eng.

5.          Baldassarre M, Pompeo A, Beznoussenko G, Castaldi C, Cortellino S, McNiven MA, et al. Dynamin participates in focal extracellular matrix degradation by invasive cells. Molecular biology of the cell. 2003 Mar;14(3):1074-84. PubMed PMID: 12631724. Pubmed Central PMCID: PMC151580. Epub 2003/03/13. eng.

6.          Chao WT, Kunz J. Focal adhesion disassembly requires clathrin-dependent endocytosis of integrins. FEBS letters. 2009 Apr 17;583(8):1337-43. PubMed PMID: 19306879. Pubmed Central PMCID: PMC2801759. Epub 2009/03/25. eng.

7.          Bhattacharya R, Kang-Decker N, Hughes DA, Mukherjee P, Shah V, McNiven MA, et al. Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2005 Oct;19(12):1692-4. PubMed PMID: 16049137. Epub 2005/07/29. eng.

8.          Lee S, Jung KY, Park J, Cho JH, Kim YC, Chang S. Synthesis of potent chemical inhibitors of dynamin GTPase. Bioorganic & medicinal chemistry letters. 2010 Aug 15;20(16):4858-64. PubMed PMID: 20621477. Epub 2010/07/14. eng.

9.          Stowell MH, Marks B, Wigge P, McMahon HT. Nucleotide-dependent conformational changes in dynamin: evidence for a mechanochemical molecular spring. Nature cell biology. 1999 May;1(1):27-32. PubMed PMID: 10559860. Epub 1999/11/13. eng.

10.       Praefcke GJ, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? Nature reviews Molecular cell biology. 2004 Feb;5(2):133-47. PubMed PMID: 15040446. Epub 2004/03/26. eng.

11.        Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, Day PM, et al. Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS pathogens. 2012;8(4):e1002657. PubMed PMID: 22536154. Pubmed Central PMCID: PMC3334892. Epub 2012/04/27. eng.

12.        Smith JL, Campos SK, Ozbun MA. Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. Journal of virology. 2007 Sep;81(18):9922-31. PubMed PMID: 17626097. Pubmed Central PMCID: PMC2045393. Epub 2007/07/13. eng.

13.        Xu B, Teng LH, Silva SD, Bijian K, Al Bashir S, Jie S, et al. The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. Cancer medicine. 2014 Feb;3(1):14-24. PubMed PMID: 24402972. Pubmed Central PMCID: PMC3930386. Epub 2014/01/10. eng.